Table S2. Survival analysis of clinical parameters.

Characteristics	P value
	OS	DFS	PFS	MFS
Gender	0.63	0.47	0.712	0.82
Age at diagnosis over median (49 y)	0.87	0.63	0.39	0.38
Smoking	0.87	0.80	0.52	0.94
Paraneoplastic syndrome	0.37	0.19	0.80	0.053
WHO type (C vs. B3 vs. B2/B3)	0.055	0.40	0.28	0.24
WHO type (C vs. B3 + B2/B3)	0.021*	0.29	0.29	0.34
Subtype of WHO type C (neuroendocrine vs. squamous vs. basaloid)	0.051	0.12	0.24	0.089
Masaoka-Koga stage	0.23	0.036*	0.29	<0.001*
Masaoka-Koga stage (III + IV vs. II)	0.076	0.009*	0.30	<0.001*
Masaoka-Koga stage (IV vs. II + III)	0.064	0.023*	0.28	<0.001*
Tumor size over median (68.5 mm)	0.39	0.29	0.091	0.027*
Surgical approach (minimally invasive vs. open + combined)	0.031*	0.52	0.27	0.83
Surgical procedure (biopsy vs. resection of intrathymic tumor vs. thymectomy)	<0.001*	0.12	0.002*	0.026*
Invasion	0.67	0.16	0.95	0.066
Invasion into lung	0.98	0.14	0.22	0.045*
Invasion into pleura	0.16	0.023*	0.72	0.001*
Invasion into pericardium	0.50	0.71	0.86	0.87
Invasion into vessels	0.22	0.047*	0.28	0.024*
Residual disease (R2 vs. R1 vs. R0)	0.23	–	–	0.86
Metastasis	0.37	0.014*	0.074	–
Metastasis to pleura	0.056	0.45	0.002*	–
Metastasis to lung	0.28	0.008*	0.099	–
Metastasis to lymph nodes	0.38	0.034*	0.55	–
Metastasis to bone	<0.001*	–	<0.001*	–
Metastasis to brain	0.44	0.23	–	–

*, significant P value (P<0.05). OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; MFS, metastasis-free survival.